Telomir Pharmaceuticals (Telomir Pharmaceuticals) Total Liabilities : $0.49 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Total Liabilities?

Telomir Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $0.49 Mil.

Telomir Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 ($3.14 Mil) to Dec. 2023 ($1.34 Mil) and declined from Dec. 2023 ($1.34 Mil) to Mar. 2024 ($0.49 Mil).

Telomir Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($0.14 Mil) to Dec. 2022 ($0.99 Mil) and increased from Dec. 2022 ($0.99 Mil) to Dec. 2023 ($1.34 Mil).

Telomir Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Telomir Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Total Liabilities Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Total Liabilities

0.14

0.99

1.34

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial				-	2.03	3.14	1.34	0.49

Telomir Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Telomir Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.336	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.34

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4.774	-	3.438
	=	1.34

Telomir Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.487	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.49

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3.503	-	3.017
	=	0.49

Telomir Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024